DarioHealth stock fell 10.22 percent on October 5

Published on 10/06/2026 at 12:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DarioHealth stock stood at USD 5.80 on Nasdaq after the October 5 session. Q2 revenue reached USD 5.2 million while gross margin rose to 62 percent.

DRIO, US23725P3082, Illustration mit AI erstellt.

DarioHealth Corp. (ISIN US23725P3082) closed at USD 5.80 on Nasdaq on October 5, 2026, down 10.22 percent from the prior close. The company is balancing a weaker top line with higher margins and a growing pipeline of contracted recurring revenue. The numbers point to a transition story rather than a simple revenue-growth case.

Margins improve in Q2

DarioHealth reported USD 5.2 million in second-quarter 2026 revenue, compared with USD 5.4 million in the year-earlier quarter and USD 5.6 million in the first quarter. According to Yahoo Finance on August 11, 2026, gross margin increased to 62 percent from 55 percent a year earlier and 57 percent in the prior quarter.

The earnings profile also improved despite the revenue decline. Net loss was USD 7.9 million in Q2 2026, versus USD 13.0 million in Q2 2025, a 39 percent improvement, while operating expenses fell 21 percent year over year, according to Yahoo Finance.

Contract points to 2027 revenue

The commercial case rests on converting signed accounts into recognized revenue. On September 17, 2026, PR Newswire reported that Dario secured a New Jersey health-plan contract representing 1.5 million covered lives through Amwell. The program is expected to launch and begin generating revenue in Q1 2027.

DarioHealth ended Q2 2026 with USD 13.1 million in contracted and late-stage annual recurring revenue, with more than 80 percent tied to multi-condition offerings, according to Yahoo Finance. That backlog offers a measurable counterweight to the near-term revenue contraction, but implementation timing remains central to the investment case.

Stock sits at yearly low

At USD 5.80, DarioHealth stock was at its 52-week low of USD 5.80 and 64.95 percent below the 52-week high of USD 16.55 on October 5, 2026. Trading volume was 26,140 shares, and the session range was USD 5.80 to USD 6.54.

Investing.com lists November 16, 2026, as the next earnings date and reports a five-analyst consensus of Strong Buy with an average 12-month price target of USD 13.60. The target is 134.48 percent above the October 5 closing price, while the latest reported quarter still showed a revenue decline.